A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
Equivalence Considerations for Orally Inhaled Products for Local Action—ISAM/IPAC-RS European Workshop Report
2012
Journal of Aerosol Medicine
Preserved Fulltext
Executive Summary T he European regulatory approach to determining equivalence of locally acting orally inhaled products (OIPs) recommends a stepwise demonstration of equivalent product performance via in vitro tests, failing that-via pharmacokinetic (PK) safety plus PK pulmonary deposition or lung imaging studies, and failing that-via pharmacodynamic (PD) or clinical studies. North American regulatory approaches do not allow equivalence determinations based
doi:10.1089/jamp.2011.0968
pmid:22413806
fatcat:6zi3hrfmovajtiu6w75hwbq6xm